A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin
NCT02967224 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 705
Last updated 2022-04-25
Summary
Primary Objective:
To demonstrate noninferiority of Toujeo versus "standard of care" basal insulin therapy measured as glycosylated hemoglobin (HbA1c) change
Secondary Objectives:
* To demonstrate superiority of Toujeo versus "standard of care" basal insulin if noninferiority is met, measured as HbA1c change.
* To compare Toujeo to other "standard of care" basal insulin in terms of patient persistence with assigned basal insulin therapy with or without intensification.
* Risk of hypoglycemia including the incidence of documented symptomatic or severe hypoglycemic events \[as defined by the American Diabetes Association (ADA\] Workgroup on Hypoglycemia).
* Change in fasting plasma glucose (FPG).
* Change in body weight.
* Differences in patient reported outcomes measured by Diabetes Treatment Satisfaction Questionnaire Status and Change Versions (DTSQs and DTSQc).
* Change in hypoglycemic control subscale (HCS)
* Healthcare resource utilization including hospitalizations and emergency department or other health care provider visits and healthcare costs.
Conditions
- Diabetes Mellitus, Type 2
Interventions
- DRUG
-
insulin glargine (U300)
Pharmaceutical form: solution Route of administration: subcutaneous
- DRUG
-
insulin glargine (U100)
Pharmaceutical form: solution Route of administration: subcutaneous
- DRUG
-
NPH insulin
Pharmaceutical form: solution Route of administration: subcutaneous
- DRUG
-
insulin detemir
Pharmaceutical form: solution Route of administration: subcutaneous
- DRUG
-
insulin degludec
Pharmaceutical form: solution Route of administration: subcutaneous
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Sciences & Operations · Sanofi
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-11-05
- Primary Completion
- 2017-10-16
- Completion
- 2017-10-16
Countries
- Brazil
- France
- Germany
- Ireland
- Romania
- Spain
- United Kingdom
Study Locations
More Related Trials
-
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
NCT02688933 ·Status: COMPLETED ·Phase: PHASE4
-
Toujeo Versus NPH Self-titration Study
NCT03389490 ·Status: COMPLETED ·Phase: PHASE4
-
Acceptability & Impact of a Diabetes Management Smartphone App (mySugr) for Spanish-literate Adults With Type 2 Diabetes
NCT05975242 ·Status: COMPLETED ·Phase: NA
-
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
NCT01569841 ·Status: COMPLETED ·Phase: PHASE3
-
A Study in Patients With Type 2 Diabetes Mellitus
NCT01435616 ·Status: COMPLETED ·Phase: PHASE3
-
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
NCT03596450 ·Status: COMPLETED ·Phase: PHASE4
-
Insulin Glulisine in Diabetes Mellitus, Type 2
NCT00174668 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin
NCT03760991 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
NCT02607306 ·Status: COMPLETED ·Phase: PHASE3
-
Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)
NCT00135941 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
NCT02128932 ·Status: COMPLETED ·Phase: PHASE3
-
Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin
NCT00135057 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes
NCT02030600 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
NCT02420262 ·Status: COMPLETED ·Phase: PHASE3
-
Tofogliflozin GLP-1 Analogue Combination Trial
NCT02537834 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin
NCT00693771 ·Status: COMPLETED ·Phase: PHASE4
-
Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition
NCT01081938 ·Status: TERMINATED ·Phase: PHASE4
-
Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults
NCT05923827 ·Status: COMPLETED ·Phase: NA
-
Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly
NCT02557620 ·Status: COMPLETED ·Phase: PHASE1
-
Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
NCT01203111 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
NCT01849289 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
NCT01952145 ·Status: COMPLETED ·Phase: PHASE3
-
Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus
NCT00467376 ·Status: COMPLETED ·Phase: PHASE3
-
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
NCT05813912 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL
NCT03406000 ·Status: COMPLETED ·Phase: PHASE4